Here's Why Cara Therapeutics Rose 12.5% in August
The company announced second-quarter 2018 earnings results and initiated a crucial late-stage clinical trial.
Wednesday, September 5, 2018
Here's Why Cara Therapeutics Rose 12.5% in August
Here's Why Cara Therapeutics Rose 12.5% in August
The company announced second-quarter 2018 earnings results and initiated a crucial late-stage clinical trial.
Related Posts:
0 comments:
Post a Comment